Idenix Pharma to raise $61.5M as it advances HCV agents
This article was originally published in Scrip
Executive Summary
Idenix Pharmaceuticals, which focuses on treatments for viral diseases, said it will sell 9.4 million shares of stock for $6.50 per share in an offering underwritten by JPMorgan.